United Therapeutics Corporation
UTHR
$556.82
-$5.27-0.94%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -1.62% | 7.38% | 6.76% | 11.71% | 17.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.62% | 7.38% | 6.76% | 11.71% | 17.22% |
| Cost of Revenue | 44.22% | 36.23% | 21.42% | 12.60% | 26.89% |
| Gross Profit | -7.66% | 4.06% | 4.93% | 11.60% | 16.05% |
| SG&A Expenses | 8.23% | 19.36% | 17.98% | 7.43% | 17.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.71% | 17.35% | 20.40% | 4.41% | 28.06% |
| Operating Income | -14.89% | -2.64% | -4.63% | 20.73% | 7.44% |
| Income Before Tax | -24.84% | 11.98% | 12.71% | 14.95% | 6.25% |
| Income Tax Expenses | -57.16% | -16.28% | 24.91% | 28.11% | 10.11% |
| Earnings from Continuing Operations | -14.68% | 20.91% | 9.58% | 11.29% | 5.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.68% | 20.91% | 9.58% | 11.29% | 5.09% |
| EBIT | -14.89% | -2.64% | -4.63% | 20.73% | 7.44% |
| EBITDA | -13.46% | -1.71% | -3.77% | 20.29% | 8.43% |
| EPS Basic | -11.93% | 24.82% | 11.58% | 9.56% | 10.00% |
| Normalized Basic EPS | -8.55% | 2.13% | -2.15% | 20.42% | 14.21% |
| EPS Diluted | -12.22% | 24.54% | 12.05% | 9.57% | 7.46% |
| Normalized Diluted EPS | -8.78% | 1.86% | -1.67% | 20.29% | 11.58% |
| Average Basic Shares Outstanding | -3.12% | -3.13% | -1.79% | 1.58% | -4.47% |
| Average Diluted Shares Outstanding | -2.88% | -2.87% | -2.27% | 1.68% | -2.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |